Innovus Pharmaceuticals has ordered 220,000 units of FlutiCare, putting the drug on pace to meet its planned launch for the fourth quarter of 2017.
FlutiCare, an over-the-counter (OTC) fluticasone propionate nasal spray, treats patients with allergic rhinitis, more commonly referred to as “allergies.”
“We are very excited about the upcoming commercial launch of our FlutiCare product in the United States,” Dr. Bassam Damaj, president and CEO of Innovus Pharma, said in a statement. “We have ordered our initial commercial batch of the product, are finalizing our on-line, Beyond Human, retail and wholesale sales and marketing efforts and are gearing up for a successful launch of FlutiCare in the fourth quarter of this year. We believe that the launch of FlutiCare should have an important impact on the gross revenues of the company.”
Innovus Pharma, headquartered in San Diego, California, develops and commercializes OTC products that target respiratory diseases with the goal of improving health and vitality.